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Background: It is hypothesized that a CXCR2 receptor antagonist would inhibit the recruitment and activation of neutrophils and other inﬂammatory
cells into the lung in subjects with cystic ﬁbrosis. The objective of this study was to evaluate the safety, tolerability and pharmacodynamics of SB-656933,
an oral CXCR2 antagonist.
Methods: 146 adult CF patients were randomized to receive either placebo or SB-656933 20 mg or 50 mg once daily for 28 days. The primary
endpoint was safety; secondary endpoints included pharmacokinetics, blood and sputum biomarkers, sputum microbiology, pulmonary function
and respiratory symptoms.
Results: SB-656933 was generally well tolerated. The most frequent adverse event was headache. Five subjects were withdrawn due to adverse
events. In subjects receiving SB-656933 50 mg, sputum neutrophils and elastase were reduced compared to baseline (probability of a true
reduction, 0.889 and 0.882 respectively), and free DNA reduced compared to placebo (probability of a true reduction, 0.967), while blood levels of
ﬁbrinogen, CRP and CXCL8 were increased. There were no changes in lung function or respiratory symptoms. Average plasma concentrations of
SB-656933 were lower than predicted based on previous studies, only breaching IC50 for ~4 h at the 50 mg dose.
Conclusions: SB-656933 was well-tolerated in adult patients with cystic ﬁbrosis. Patients receiving a daily dose of 50 mg showed trends for
improvement in sputum inﬂammatory biomarkers despite potential blunting of effects by lower than expected plasma concentrations. Although the
increase in systemic inﬂammatory markers requires further evaluation, CXCR2 antagonism may be a useful approach for modulating airway
inﬂammation in patients with cystic ﬁbrosis. Clinical trial registered with www.clinicaltrials.gov (NCT00903201).
© 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: CXCR2; Cystic ﬁbrosis; Chemokine; Clinical trial; Human; Inﬂammation1. Introduction
Cystic fibrosis (CF) is the most common lethal autosomal
recessive disease among Caucasians. CF lung disease is charac-⁎ Corresponding author. Tel.: +1 610 270 4026; fax: +1 610 270 5360.
E-mail address: aili.l.lazaar@gsk.com (A.L. Lazaar).
1569-1993/$ -see front matter © 2012 European Cystic Fibrosis Society. Pub
http://dx.doi.org/10.1016/j.jcf.2012.08.016lishedterized by airway obstruction, infection, neutrophilic inflammation
and progressive bronchiectasis. Median survival is approximately
37 years with over 90% of patients dying from complications of
pulmonary disease. It is postulated that the recruitment and
activation of inflammatory cells in the airways contribute
significantly to the pulmonary pathophysiology of CF and that
the degree of inflammation is excessive [1]. This was the rationaleby Elsevier B.V. All rights reserved.
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azithromycin [4]. To date, no anti-inflammatory therapy has been
shown to convincingly reduce markers of airway inflammation in
CF, however, several approaches are being explored [5].
Small studies in CF demonstrated an inverse relationship
between lung function and sputum levels of CXCL8 (IL-8), total
cell counts, neutrophil counts, neutrophil elastase, and
myeloperoxidase [6–8]. CXCL8 was the first identified member
of a growing family of pro-inflammatory chemokines that attract
and activate immune and inflammatory cells, particularly
neutrophils. The CXC chemokines function as agonists at
G-protein-coupled transmembrane cell surface receptors on target
cells. The CXC receptors (CXCR1 and CXCR2) are located on
neutrophils, subsets of T-cells, macrophages, dendritic cells, and
mast cells. Their agonists contain the glutamic acid–leucine–
arginine (ELR+) sequence before the first cysteine residue.
CXCR1 is selectively activated by CXCL6 and CXCL8, while
the CXCR2 receptor is stimulated potently by CXCL1-3, and
CXCL5-8 [9].
Based upon pre-clinical evidence, it has been proposed that a
CXCR2 receptor antagonist would specifically inhibit the
recruitment and activation of neutrophils and other inflammatory
cells into the lung in subjects with CF. SB-656933 is a selective
CXCR2 antagonist in development as a novel, once-daily oral
anti-inflammatory agent for the maintenance treatment of CF
[10,11]. It is hypothesized that selective antagonism of CXCR2,
by inhibiting neutrophil recruitment but not microbial killing
(thought to be mediated by CXCR1) [12], would potentially
restore the balance between host defense and tissue damage
mediated by neutrophil products. The compound represents a
novel class of agents compared with those previously approved
for CF and by inhibiting airway inflammation over time would be
expected to stabilize lung function.
2. Methods
2.1. Study design
This study (GSK protocol CF2110399, NCT00903201) was a
randomized, double blind, parallel group, placebo-controlled trial
with 3 treatment arms (Fig. 1). Subjects were recruited from 31
sites in the US, France, Germany, and Israel. All subjects
attended a screening visit (Visit 1) at which time their eligibilityS
Randomization
Screening Baseline
Visit 1 2b2a
Up to -28 -3 to-7 1Study day
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Fig. 1. Study sfor study inclusion was assessed. Baseline assessments included
spirometry, induced sputum and sampling for blood biomarkers.
Eligible subjects were randomized to receive either placebo or
active treatment for 28 days. On Day 14 (Visit 3), assessments
included spirometry and sampling of blood for biomarkers and
pharmacokinetics. On Day 28 (Visit 5), end of treatment
assessments included induced sputum and sampling of blood
for biomarkers and pharmacokinetics. Patients completed a daily
symptom diary throughout the treatment period. Subjects also
returned for a follow-up visit (Visit 6) approximately 7 to 14 days
after last dose of study medication.
The study protocol, any amendments, informed consent, and
other information that required pre-approval were reviewed and
approved by a national, regional, or investigational center ethics
committee. The study was conducted in accordance with good
clinical practice and all regulatory requirements, including, where
applicable, those originating from the Declaration of Helsinki.
All subjects provided written informed consent before treatment.2.2. Endpoints
The primary endpoint for this study was the safety of
SB-656933 in subjects with cystic fibrosis, including adverse
events, vital signs and clinical laboratory assessments, electro-
cardiographic (ECG) parameters, and CF exacerbations (includ-
ing withdrawals, time to exacerbations and/or new antibiotic
prescription).
Secondary endpoints included: 1) qualitative sputum
microbiology for Pseudomonas aeruginosa and Staphylococcus
aureus; 2) induced sputum neutrophil number (cells/mL) and
percentage; 3) sputum inflammatory biomarkers (neutrophil
elastase (NE), myeloperoxidase (MPO), free DNA and PGP
peptides); 4) serum and plasma markers of inflammation
(fibrinogen, CRP, CC-16, MMP8, MMP9, SP-D, CXCL8); 5)
forced expiratory volume in one second (FEV1) and forced vital
capacity (FVC); and 6) plasma SB-656933 concentrations and
pharmacokinetic parameters including area under the plasma
drug concentration versus time curve (AUC0–4, AUC0–t),
maximum observed plasma drug concentration (Cmax) and time
to maximum observed plasma drug concentration (Tmax). The
Daily Respiratory Symptom Diary for Cystic Fibrosis (Self
Reported Version) was included as an exploratory endpoint [13].Placebo
B-656933 20 mg 
Treatment Follow up
53 4 6
14 21 28 35-42
B-656933 50 mg
chematic.
Table 1
Patient baseline demographic and clinical characteristics.
Placebo
(n=61)
SB-656933
20 mg
(n=44)
SB-656933
50 mg
(n=41)
Age, years (range) 29.5 (18–54) 32.9 (18–70) 31.3 (18–63)
Male % 64 64 59
FEV1 % predicted
(range)
66.5 (61.9–71.1) 69.8 (64.2–75.3) 65.4 (59.1–71.7)
BMI, kg/m2 (range) 22.58 (17–41.9) 22.93 (18.5–34.2) 22.88 (17.7–34.6)
Azithromycin, n (%) 35 (57%) 30 (68%) 18 (44%)
Pulmozyme, n (%) 31 (51%) 25 (57%) 29 (71%)
ICS, n (%) 31 (51%) 22 (50%) 20 (49%)
Pseudomonas in
sputum, n (%)
37 (61%) 27 (61%) 25 (61%)
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Males or females ≥18 years of age with a diagnosis of CF
were eligible to participate. Subjects were not permitted to be on
inhaled antibiotics during the study commencing from one week
prior to dosing until the final PK draw, in order to minimize
variability. Maintenance therapy with inhaled hypertonic saline,
inhaled DNase or inhaled corticosteroids was permitted provided
there were no changes to therapy during the study. A detailed
description of inclusion and exclusion criteria is available in the
online supplement.
2.4. Biomarkers
Detailed methods for sputum processing and biomarker
analysis can be found in the online supplement.
2.5. Respiratory symptoms
The “Daily Respiratory Diary Card for Cystic Fibrosis— Self
Reported (Ages 12+ years)”, also referred to as CFRSD
(Copyright 2007 University of Washington) [13] was completed
by all subjects. A detailed description is available in the online
supplement.
2.6. Statistical methods
The sample size was primarily based on feasibility since it was
not viable to power the study on the primary endpoints of safety
and tolerability or with respect to any of the sputum or blood
biomarkers. Given the small number of subjects enrolled in this
study, these data presented in summary fashion, as there was
insufficient power to perform a formal statistical analysis of safety.
A pre-specified log transformation was applied to all biomarker
data to improve compatibility with the normal distribution
assumption. The biomarker data are presented as geometric
means. An analysis of neutrophil cell counts and ratio to baseline
was performed for loge-transformed data using a fixed effects
repeated measures analysis, including treatment group and visit as
fixed effects. Pre-treatment sputum neutrophil numbers were fitted
as a response (all baseline data were assigned to one treatment
group called baseline, regardless of the treatment the subject
went on to receive, and these values were also fitted as a
response). Estimates of the treatment differences (SB-656933 vs.
placebo) were calculated and presented with two-sided 90%
confidence intervals (using the pooled estimate of variance).
Bayesian probabilities were produced to provide the probability
of SB-656933 demonstrating a true treatment effect greater than
placebo. Non-informative priors were used reflecting that no
prior information on the treatment effect was made in the
analyses. With non-informative priors, these results approximate
to 1 minus a 1-sided p-value. The same method of analysis was
applied to the remaining sputum biomarkers, as well as to serum
and plasma biomarkers. Where appropriate, BQL values were
imputed with 1/2 LLQ limit value and AQLs were imputed with
the AQL limit value.An exploratory TOBIT analysis was performed on biomarkers
CRP, CXCL-8, free DNA, MPO, NE and SP-D, as these data
incurred values below the quantification limit (BQL) and/or
above the quantification limit (AQL). TOBIT analysis is an
optimization procedure that obtains parameter estimates from a
model that describes the distribution by fitting the model to both
the observed and unobserved data; this type of analysis enables
more accurate estimation of the mean and variance of a truncated
distribution, as in the case with BQLs and AQLs. A table quan-
tifying the number of out-of-range data points is included in the
online supplement (Table S1).
Lung function data (change from baseline FEV1 and FVC)
were analyzed in a similar way to that described for sputum
neutrophils. However, the statistical analysis for change from
baseline lung function measures included the covariate “day” as
a fixed effect in the model as well.
Two interim analyses were performed during the conduct of
this study. A detailed description of the interim analysis plan can
be found in the online supplement.3. Results
3.1. Safety
A total of 146 subjects were randomized according to a
planned 4:3:3 placebo:active arms ratio (Figure S1). Of these, 61
subjects received at least one dose of placebo, 44 subjects
received at least one dose of SB-656933 20 mg and 41subjects
received at least one dose of SB-656933 50 mg. Demographic
information is included in Table 1.
There were a similar number of reported adverse events across
all treatment groups (Table 2). The most frequent AE reported
across all groups was headache. There were trends for increased
incidence of pyrexia, hemoptysis, and nasopharyngitis in the
subjects receiving SB-656933, but these were not considered
drug-related. The most frequent drug-related AE reported across
all groups was also headache.
Five subjects were withdrawn from the study due to AEs that
were considered study drug related, including one on placebo (CF
exacerbation) and 4 receiving SB-656933 20 mg: throat tightness
(one patient); testicular pressure (one patient); abdominal pain,
Table 2
Adverse events occurring ≥5% in any group.
System organ class
(preferred term)
Placebo
(n=61)
SB-656933
20 mg
(n=44)
SB-656933
50 mg
(n=41)
Any event 46 (75%) 32 (73%) 32 (78%)
Respiratory, thoracic and
mediastinal disorders
Cough 12 (20%) 5 (11%) 7 (17%)
Sputum increased 9 (15%) 2 (5%) 2 (5%)
Oropharyngeal pain 4 (7%) 1 (2%) 3 (7%)
Hemoptysis 1 (2%) 4 (9%) 2 (5%)
Nasal congestion 3 (5%) 0 3 (7%)
Pulmonary congestion 0 1 (2%) 2 (5%)
Rhinorrhea 0 1 (2%) 2 (5%)
Nervous system disorders
Headache 16 (26%) 13 (30%) 7 (17%)
General disorders and
administration site conditions
Chest discomfort 5 (8%) 3 (7%) 5 (12%)
Pyrexia 0 4 (9%) 2 (5%)
Infections and infestations
Infective pulmonary exacerbation
of cystic fibrosis
5 (8%) 4 (9%) 5 (12%)
Nasopharyngitis 3 (5%) 4 (9%) 4 (10%)
Gastrointestinal disorders
Diarrhea 3 (5%) 3 (7%) 3 (7%)
Constipation 1 (2%) 1 (2%) 2 (5%)
Flatulence 1 (2%) 0 2 (5%)
Investigations
C-reactive protein increased 1 (2%) 0 2 (5%)
Musculoskeletal and
connective tissue disorders
Musculoskeletal pain 0 0 2 (5%)
Reproductive system and breast disorders
Scrotal pain 0 0 1 (2%)
Spontaneous penile erection 0 0 1 (2%)
Testicular pain 0 1 (2%) 0
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Fig. 2. The effect of SB-656933 on sputum biomarkers at Day 28. Left: adjusted
geometric mean±90% CI of the ratio to baseline for neutrophil numbers (top),
neutrophil elastase (middle) and myeloperoxidase (bottom). —placebo, —
SB-656933 20 mg, —SB-656933 50 mg. Right: adjusted geometric mean±90%
CI for treatment ratio to placebo for SB-656933 20 mg ( ) and SB-656933 50 mg
( ).
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headache (single patient); mood swings, fatigue, irritability and
depression (single patient).
A total of six subjects (two on each treatment regimen)
reported serious adverse events. These included: CF exacerbation
(two on placebo, one each on SB-656933 20 mg and 50 mg),
intestinal obstruction (SB-656933 20 mg) and hemoptysis
(SB-656933 50 mg). None of the CF exacerbations were
associated with new infiltrates on CXR. All SAEs were resolved
and there were no deaths.
There were no clinically meaningful findings following
review of clinical laboratories, vital signs or ECGs for any
subject in this study. All individual subject blood neutrophil
counts remained in the non-neutropenic range throughout this
study, with no subject having an absolute blood neutrophil count
below the threshold of 1.5×109 cells/L. Finally, there was no
overall change in bacterial colonization or semi-quantitative
density across the treatment groups (data not shown).
3.2. Sputum biomarkers
Treatment with SB-656933 50 mg for 28 days resulted in a
reduction of sputum neutrophils by 31% (90% CI −48, −10)compared to baseline and by 23% (90% CI −45, +9,
probability=0.889) compared to placebo (Fig. 2). Ad hoc
analysis suggested that these results were driven by two
responders who appeared to be outliers, despite baseline cell
counts that were consistent with those of other subjects and no a
priori reason to expect they were anomalous. In contrast, sputum
neutrophils were unexpectedly increased in patients receiving
SB-656933 20 mg compared to baseline and to placebo (+26%,
90% CI −11, +78, probability=0.133) (Fig. 2). There was a
slight decrease observed in percentage neutrophils compared to
baseline for all three treatment groups; however, there was no
treatment difference observed on Day 28 when comparing
SB-656933 20 mg or SB-656933 50 mg with placebo (data
not shown). A similar pattern of results to those for sputum
neutrophil numbers was observed for sputum macrophages and
for the total cell count (data not shown).
Levels of sputum neutrophil elastase were decreased by 26%
(90% CI −44, −2) compared to baseline and by 23% (90%
CI −46, +11, probability=0.882) compared to placebo in
subjects receiving SB-656933 50 mg (Fig. 2). There was a trend
for a decrease in sputumMPO compared to baseline (−15%; 90%
CI −30, +2) and to placebo (−17%; 90% CI −33, +4,
probability=0.914) (Fig. 2). The 50 mg dose also resulted in a
significant decrease in sputum free DNA when compared to
placebo (−25%; 90% CI −43, −3, probability=0.967), though
not when compared to baseline (data not shown). This is likely
due to the fact that free DNA levels increased over time in
245R.B. Moss et al. / Journal of Cystic Fibrosis 12 (2012) 241–248subjects on placebo (+24%; 90% CI: + 5, +48), while they
remained stable in subjects receiving the higher dose of
SB-656933. There were no differences in free DNA between
placebo and SB-656933 20 mg at Day 28 (data not shown).
Sputum PGP on Day 28 was increased compared to baseline
for all three treatment groups (Supplement Table 2). However,
there was no treatment difference observed on when comparing
SB-656933 20 mg or 50 mg with placebo.
3.3. Blood biomarkers
In subjects receiving SB-656933 50 mg, there was an
average increase in serum fibrinogen of 14% (90% CI +9, +20)
on Day 28 when compared to baseline and an increase of 11%
(90% CI+4, +18, probability=0.996) when compared to
subjects on placebo (Fig. 3). The pattern of results for CRP was
similar but more pronounced than those observed for fibrinogen,
with an observed increase of 78% on Day 28 compared to
placebo (90% CI +33, +139, probability=0.999) (Fig. 3). In
addition, there was a significant increase in serum CXCL8 at Day
14 when compared to baseline (+84%; 90% CI +60, +111) and
to placebo (+84%; 90% CI +56, +117), which appeared to be
dose-dependent, unlike fibrinogen and CRP where 20 mg did not
differ from placebo (Fig. 3). The increase in CXCL8 did not
increase further at Day 28.
There were no significant differences in other blood
biomarkers, including CC-16, SP-D, MMP-8 and MMP-9.0.5
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Fig. 3. The effect of SB-656933 on blood biomarkers at Day 14 and Day 28. Left:
adjusted geometric mean±90% CI of the ratio to baseline for fibrinogen (top),
C-reactive protein (middle) and CXCL8 (bottom). —placebo, —SB-656933
20 mg, —SB-656933 50 mg. Right: adjusted geometric mean±90% CI for
treatment ratio to placebo for SB-656933 20 mg ( ) and SB-656933 50 mg ( ).These data are summarized in the online supplement (Table S2).
The results of the TOBIT analysis were in line with the results
from the analysis using the imputation method. Exploratory
analysis of age and gender effects revealed no consistent pattern.
For example, females reported higher MPO levels compared to
males, whereas age had a significant effect on CXCL8. Further
exploration of the data did not show any clear reason for a
significant age effect (data not shown).
One-sided multivariate analysis of sputum and blood
biomarkers was performed. A first cluster of lung-derived
markers included sputum total cell count, sputumNE and sputum
MPO (both adjusted for total protein), sputum weight, free DNA,
sputum PGP and serum SP-D. A second cluster included
neutrophil/CXCR2-associated markers: sputum NE, sputum
MPO, sputum neutrophil number, serum IL-8 and serum
MMP-8. The lung-derived cluster did not show a significant
improvement for SB-656933 20 mg when compared to placebo
(p=0.450). However, there was a significant improvement (at the
10% level) for SB-656933 50 mg when compared to placebo
(p=0.065) on Day 28. There was no significant improvement for
either SB-656933 treatment compared to placebo for the second
cluster of neutrophil/CXCR2-associated endpoints on Day 28.
3.4. Lung function
There was a non-significant decrease in FEV1 for SB-656933
20 mg (−0.062 L, 90% CI −0.150, +0.026) and for SB-656933
50 mg (−0.044 L, 90% CI −0.131, +0.044) when comparing
active treatment with placebo at Day 28, although the study was
not powered to detect a difference. There was no clinically
significant change in FVC for SB-656933 20 mg or 50 mg when
compared to placebo (data not shown).
3.5. Pharmacokinetics
A summary of the pharmacokinetic parameters for SB-656933
20 mg and 50 mg is presented in Table 3. Pharmacokinetic
results differed markedly from previous clinical investiga-
tions of SB-656933 [14], including the pharmacokinetic
parameters determined from a separate group of nine CF
patients who participated in a previous study (http://www.
gsk-clinicalstudyregister.com). PK parameters between each
sampling occasion (Days 1 and 28) were similar, indicating
that there was no notable accumulation of SB-656933, which
would not have been predicted based on prior data with this
compound. On Day 1 and Day 28, the average plasma
SB-656933 concentrations were less than IC50 (331 ng/mL)
following SB-656933 20 mg dosing, and only breached IC50
for approximately 4 h following SB-565933 50 mg dosing.
3.6. Health outcomes
The most commonly reported symptoms were cough, produc-
tive cough and feeling tired (data not shown). Some improvements
in daily symptoms were observed in all treatment groups, but
categorical analyses suggested that the numbers with improvement
were too small to be meaningful. Decreases in frequency were
Table 3
Derived plasma pharmacokinetic parameters of SB-656933.
Parameter Treatment Visit N Geometric mean (SD logs) a 95% CI of geometric mean % CVb
AUC0–4 (ng.h/mL) SB-656933 20 mg Day 1 44 741.1 (0.585) 625.4–892.3 63.8
Day 28 38 592.3 (0.790) 456.8–768.0 93.1
SB-656933 50 mg Day 1 41 2227.6 (0.428) 1946.2–2549.7 44.8
Day 28 39 1906.8 (0.738) 1501.2–2421.9 85.1
AUC0–t (ng.h/mL) SB-656933 20 mg Day 1 44 1272.5 (0.408) 1124.0–1440.5 42.6
Day 28 38 592.3 (0790) 456.8–768.0 93.1
SB-656933 50 mg Day 1 41 3537.6 (0.430) 3089.1–4051.3 45.0
Day 28 39 1906.8 (0.738) 1501.2–2421.9 85.1
Cmax (ng/mL) SB-656933 20 mg Day 1 44 342.89 (0.502) 294.31–399.48 53.6
Day 28 38 222.86 (0.957) 162.71–305.24 122.4
SB-656933 50 mg Day 1 41 967.78 (0.509) 824.22–1136.35 54.3
Day 28 39 778.04 (0.595) 641.57–943.53 65.2
Tmax (h)
b SB-656933 20 mg Day 1 44 1.94 (0.50–4.00) – –
Day 28 38 2.11 (0.97–4.08) – –
SB-656933 50 mg Day 1 41 1.74 (0.50–4.25) – –
Day 28 39 1.84 (0.95–4.00) – –
a Minimum and maximum ranges reported for Tmax.
b Data not log transformed.
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there was no respiratory symptom for which both active treatment
groups demonstrated a sustained decrease from baseline in
frequency rank.
4. Discussion
This study was conducted to assess the safety and tolerability
of 28 days daily oral dosing with SB-656933 in subjects with
cystic fibrosis. When assessing safety, specific attention was paid
to the following areas: incidence of CF exacerbations, changes
in sputum microbiology, evidence for an effect on peripheral
blood neutrophils (neutropenia in particular) and evidence for
epididymitis, based on the known pre-clinical profile. The
inclusion of a placebo arm was intended to allow for a valid
evaluation of adverse events attributable to SB-656933 versus
those independent of SB-656933. The selected doses had
previously been shown to reduce ex vivo CXCL1-induced
CD11b surface expression, an activation biomarker, on peripheral
blood neutrophils from healthy subjects and a small number of
adults with CF, and were expected to have pharmacological
activity based upon the results of an ozone challenge study in
healthy adult subjects [14].
This study demonstrated that SB-656933 is generally well
tolerated when doses of 20 mg or 50 mg are administered once
daily for 28 days to patients with CF. The drug-related adverse
events which led to the premature discontinuation of five subjects
resolved prior to study completion, and importantly, the number
of subjects who reported a CF exacerbation was comparable
across treatment groups.
Laboratory investigations demonstrated that peripheral blood
neutrophil counts remained stable throughout the 28 day dosing
period, with no instances of neutropenia, consistent with data
obtained on repeat dosing in healthy volunteers. Overall, the
distribution and semi-quantitative density of P. aeruginosa and
S. aureus in sputum did not change following 28 days dosing
with SB-656933. These data need to be interpreted cautiously, asquantitative bacterial counts were not performed, nor was there
screening for the emergence of new bacterial organisms other
than S. aureus or P. aeruginosa.
The increased blood levels of fibrinogen and CRP are not
easily explained with the available data. While CRP levels are
known to fluctuate in patients with CF, the sustained increase was
not associated with specific signs or symptoms of adverse effects
in these patients. The increase in CRP was seen at 14 days, and
was sustained over the remaining dosing period. In other patient
groups, such as chronic obstructive pulmonary disease (COPD) or
cardiovascular disease, elevated fibrinogen has been associated
with adverse outcomes [15–17]. Whether the same is true in
patients with CF is unknown. Further studies are needed to
determine how early the increases in CRP and fibrinogen occur
and whether they are associated with an increase in IL-6, which
was not measured in this study.
For subjects receiving SB-656933 50 mg, there was an
approximate 30% decrease in sputum neutrophils compared to
baseline levels. The observation that sputum neutrophils also
declined in patients on placebo likely contributed to the lack of
significance, although the study was not powered to detect a
difference. In addition, the unexpected increases in sputum
neutrophils in patients on SB-656933 20 mg cannot be explained
by the AE profile, and were not associated with higher levels of
CRP compared to the other treatment groups. Despite the modest
effect on sputum neutrophils, a more consistent decrease in sputum
neutrophil elastase and myeloperoxidase was seen in patients
receiving SB-656933 50 mg. In addition, while sputum free DNA
increased in patients on placebo or SB-656933 20 mg, free DNA
levels remained stable or decreased in patients on 50 mg. This
could mean that more DNAwas released in the absence of inhaled
antibiotics; alternatively, this could merely reflect the increased use
of Pulmozyme in the 50 mg group. Taken together, these data
suggest that SB-656933 50 mg reduced neutrophil activation in
the lung, which is consistent with reports that changes in
neutrophil-associated biomarkers occur before changes in neutro-
phil burden in CF sputum [18]. In contrast, sputum PGP levels
247R.B. Moss et al. / Journal of Cystic Fibrosis 12 (2012) 241–248were increased in all treatment groups. As PGP is a collagen
breakdown product, these data likely reflect ongoing inflammation
and tissue remodeling in the lung. We speculate that a decrease in
sputum PGP may only be observed after prolonged dosing with
more sustained reductions in neutrophil activation.
No significant changes in serum or plasma biomarkers were
observed in subjects receiving SB-656933, with the exception
of CC-16 and CXCL8. CC-16, a marker of acute lung epithelial
cell injury and permeability, was decreased at Day 14 in all
subjects, including those on placebo, compared to baseline, but
then increased back near baseline by Day 28. Interestingly, the
baseline level of CC-16 for all subjects was significantly lower
than the reported normal range in healthy volunteers [19]. This
is consistent with data obtained in other lung diseases such as
COPD [20], as well as in a non-interventional biomarker study
performed in patients with CF [21]. In contrast, blood levels of
CXCL8 were increased in a dose-dependent manner in subjects
receiving SB-656933 (sputum CXCL8 levels were not measured).
The etiology of this systemic increase is unclear and does not seem
to be associated with any specific adverse event profile. One
possibility is that antagonism of the natural CXCL8 receptor may
result in demargination of the existing chemokine pool. Alterna-
tively, it is possible that CXCR2 normally scavenges free CXCL8,
as has been observed with other chemokine receptors [22] and
when the receptor is blocked, this removalmechanism is impaired.
There are no published data establishing that blockade of the
CXCL8 receptor results in a feedback loop that stimulates agonist
production, although exploratory analysis of the current data
suggested a relationship between SB-656933 concentration in the
plasma and CXCL8 increase (data not shown). In addition,
elevated expression of KC, the murine homologue of CXCL8, in
bronchoalveolar lavage fluid was observed in mice exposed to
cigarette smoke and treated with a small molecule inhibitor of
CXCR1/2; this effect was not seen in air-exposed animals treated
with inhibitor alone, suggesting the possibility of a feedback loop
in the setting of inflammation. However, the increased expression
of KC did not affect the ability of the compound to reduce
smoke-induced neutrophilic inflammation [23].
The doses selected for this study were expected to inhibit
CD11b up-regulation by approximately 50%, based on previous
in vitro and ex vivo studies. Notably, on Day 1 and Day 28, the
average plasma SB-656933 concentrations were significantly
lower than the exposures previously observed to reduce agonist-
induced CD11b expression on neutrophils by 50% [24]. These
data are surprising given previous pharmacokinetic data reported
during clinical investigations in healthy volunteers [14] and in a
single dose study in 9 adult patients with CF (http://www.gsk-
clinicalstudyregister.com), where the accumulation ratio was
predicted to be 1.6 to 1.8 (healthy subjects) or 1.05 to 2.15 (CF),
respectively. Based on these data, dosing for this study was
selected on a conservative estimate predicting a 2 fold accumu-
lation, in order to maintain adequate safety margins. The higher
than expected clearance of SB-656933, with no evidence of
accumulation, may therefore provide some explanation for lack of
more robust effect on pharmacodynamic biomarkers and health
outcomes for this study. It has been demonstrated previously, for a
range of small molecules, that PK parameters in CF patients varyconsiderably compared to those in healthy subjects. An enabling
study in CF patients with this compound ultimately proved
inconclusive in this regard, and the observed PK from this study
could not have been predicted based upon either the healthy
volunteer or limited prior CF patient data. The reason for the
difference in pharmacokinetics between the two earlier and
present CF subject groups cannot be readily explained, although
the clearance and distribution characteristics of the compound
were markedly different in the CF population. Future studies with
SB-656933 in CF would need to consider dosing regimens of
twice or three times daily in order to maximize time at or near the
IC50.
In conclusion, SB-656933 was generally well tolerated
following 28 days dosing with 20 mg and 50 mg. There was no
specific adverse event profile associated with active treatment
including exacerbations, changes in sputum microbiology, or
peripheral blood neutropenia, although serum drug concentrations
were lower than expected. Extensive biomarker sampling
suggested reduced sputum neutrophil activation in patients
receiving the higher 50 mg dose of SB-656933, although patients
receiving the 20 mg dose demonstrated opposite effects, which
could not be explained by differences in demographics or
pharmacokinetics. While some of the sputum biomarker data are
encouraging, longer term dosing at pharmacologically active
exposures will be necessary to fully assess the anti-inflammatory
potential as well as the significance of elevated systemic in-
flammation, and to determine whether treatment with SB-656933
affects clinical outcomes such as lung function or respiratory
symptoms in patients with CF.
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